CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
A3309 +1 moredrug
Likely dose
A3309 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01038687
NCT01038687Phase 2Completed
CompareCT.gov

Effects of A3309, an Ileal Bile Acid Transport Inhibitor, on Gastrointestinal and Colonic Motor Functions in Female Patients With Functional Constipation

Michael Camilleri, MD·interventional·Posted Dec 24, 2009·Updated Sep 4, 2020

In Brief

A Phase 2 clinical trial evaluating A3309 and placebo for Functional Constipation. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFunctional Constipation
CountriesUnited States
CollaboratorsNational Center for Research Resources (NCRR)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 24, 2009
Enrollment StartJan 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.5 years ago

Interventions

A3309drug

A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets

placebodrug

placebo